In a phase I/II trial, the first bicistronic anti-CD19/CD22 CAR-T cells AUTO3, followed by pembrolizumab, showed acceptable safety profiles in R/R DLBCL patients. Here, CD22 is linked to diffuse large B-cell lymphoma.